Glenmark Rolls Out Generic Xalatan in US, Targets USD 113M Market
With the launch of Latanoprost Ophthalmic Solution 0.005% (0.05 mg/mL), Glenmark has introduced its fourth ophthalmic product, expanding its portfolio
Written By : Farhat Nasim
Published On 2025-02-14 07:50 GMT | Update On 2025-02-14 07:50 GMT
Glenmark Pharma USA launches Epinephrine Injection
New Delhi: Glenmark Pharmaceuticals on Friday said its subsidiary has launched generic medication to treat glaucoma in the US market. Glenmark Pharmaceuticals Inc, USA has launched Latanoprost ophthalmic solution, 0.005 per cent (0.05 mg/mL) in the market, the Mumbai-based drug maker said in a statement.
The company's product is therapeutically equivalent to Upjohn US LLC's reference listed drug, Xalatan Ophthalmic Solution, it added.
According to IQVIA, sales data for the 12-month period ending December 2024, the Xalatan Ophthalmic Solution achieved annual sales of around USD 113.5 million.
"We are excited to announce the launch of our 4th ophthalmic product, Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), growing our portfolio of products within the ophthalmic channel," Marc Kikuchi, President & Business Head, North America said.
This addition highlights company's commitment to meeting market needs and providing quality solutions for customers, he added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.